Develop More Effective, Differentiated & Transformative Therapies
for Sporadic & Familial ALS

Following monumental progress in 2023, the ALS treatment landscape is surging with novel innovation to navigate the complex, multifactorial nature of motor neuron degeneration and develop more truly transformative drugs for sporadic and familial ALS.

Capitalizing on rapid pipeline progress and emerging industry investment, the 3rd Annual ALS Drug Development Summit returns to Boston, providing a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.  

This May, join your industry colleagues across discovery, preclinical, clinical, regulatory, and commercial from the likes of Biogen, AbbVie, NeuroSense, Mitsubishi, Sanofi, Takeda, Novartis, and more. 

World-Class Speaker Faculty Includes:

Download the New Event Guide for Information on:

  • 40+ Expert Speaker Faculty
  • 10+ New Presenting Companies
  • Full access to the 3-day conference agenda
  • Pre-conference workshop day details
  • Audience Breakdown
  • & more

Previously Attending Companies Include:

previously attending companies
3rd ALS Drug Development Summit
ALS Drug Development Summit CNS
ALS Drug Development Summit Onsite

Hear from your 2024 Speakers:

Mansuo Lu Shannon - Prevail Therapeutics

“A great summit to connect Preclinical and Clinical thought leaders on ALS and to garner recent progress for breakthrough ALS therapies.” 

Mansuo Lu Shannon, Chief Scientific Officer, Prevail Therapeutics 

prevail_therapeutics_logo
Denali Therapeutics Logo (PRNewsFoto/Denali Therapeutics Inc.)

“ALS Summit brings together experts across basic scientific research, biotech, pharma, patient advocacy groups to the same room for vibrant and engaged discussions. The program captures the key progress and development in the field as well as emerging technologies and science, but still nimble and focused not to overwhelm the attendees!”

Fen Haung, Director, Translational Medicine, Denali 

Fen Huang

Proud to Partner With:

Oxford BioDynamics Plc
AA-logo-24-blue
bit bio
PRC_Clinical_20th_Logo_CMYK
NS-Baseline2020
BrainXell
ARG_Logo (5)
Catalent NEW
LogoAndHeaders
Unlearn_logo-black
Lockup - Red Orange

Other Events in the World CNS Series: